Tadnersen

RNA / oligonucleotide

Also known as BIIB078

DiscontinuedC9ORF72 (chromosome 9 open reading frame 72)No recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued, after a negative readout

Randomized, double-blind, placebo-controlled Phase 1 (NCT03626012) in C9orf72-associated ALS; no reduction in neurofilament, no benefit on clinical outcomes versus placebo; sponsor discontinued development. Follow-up study NCT04288856 terminated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Other / comorbidity
NCT03626012 · Biogen
2018-09-10 – 2021-11-17 · Amyotrophic Lateral Sclerosis
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.